Drug
Plozasiran clinical trials
- studies test it
- 11
- open now
- 1
- in phase 3
- 7
- first study started
- 2019
Keep track of what changes. Save the plozasiran studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 3
- Phase 3
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 0
Arrowhead Pharmaceuticals (10) · Visirna Therapeutics HK Limited (1)
Studies
Open first, then newest update. How each study uses plozasiran is read from its arms, and is right about nine times in ten.
Testing it · 11
- Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute PancreatitisRecruitingPhase 3Arrowhead PharmaceuticalsNCT06880770Written as Plozasiran
- Study of Plozasiran in Adults With Severe HypertriglyceridemiaCompletedPhase 3Arrowhead PharmaceuticalsNCT06347016Written as Plozasiran Injection
- Study of Plozasiran (ARO-APOC3) in Adults With Severe HypertriglyceridemiaCompletedPhase 3Arrowhead PharmaceuticalsNCT06347003Written as Plozasiran Injection
- Long-Term Safety and Efficacy of Plozasiran in Adults With HypertriglyceridemiaActive, not recruitingPhase 3Arrowhead PharmaceuticalsNCT06822790Written as Plozasiran Injection
- Phase 3 Study of Plozasiran in Adults With HypertriglyceridemiaCompletedPhase 3Arrowhead PharmaceuticalsNCT06347133Written as Plozasiran Injection
- Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)CompletedPhase 3Arrowhead PharmaceuticalsNCT05089084Written as Plozasiran
- Study of ARO-APOC3 in Adults With DyslipidemiaCompletedPhase 2Arrowhead PharmaceuticalsNCT05413135Written as ARO-APOC3
- Study of Plozasiran (ARO-APOC3) in Adults With Mixed DyslipidemiaCompletedPhase 2Arrowhead PharmaceuticalsNCT04998201Written as ARO-APOC3
- Study to Evaluate ARO-APOC3 in Adults With Severe HypertriglyceridemiaCompletedPhase 2Arrowhead PharmaceuticalsNCT04720534Written as ARO-APOC3
- A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia SyndromeCompletedPhase 3Visirna Therapeutics HK LimitedNCT05902598Written as Plozasiran
- Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)CompletedPhase 1Arrowhead PharmaceuticalsNCT03783377Written as ARO-APOC3
Codes
What other systems call plozasiran · ClinicalTrials.gg INT002109
- MeSH (NLM) C000731231plozasiranConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) XG9ARL6P25PLOZASIRANConfirmed FDA, NLM, Wikidata
- Wikidata Q136334524PlozasiranConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C203193PlozasiranOne source FDA
- DrugBank DB18997One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731231 | plozasiran | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | XG9ARL6P25 | PLOZASIRAN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q136334524 | Plozasiran | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C203193 | Plozasiran | One source FDA |
| DrugBank | DB18997 | — | One source Wikidata |
Also registered as plozasiran sodium (UNII U93HYZ4QU8).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.